Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Regulus Therapeutics Released Topline Data From The Second Cohort Of Patients In Its Phase 1b Multiple-Ascending Dose Trial Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Author: Benzinga Newsdesk | March 12, 2024 06:32am
  • Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses
  • Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2
  • Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024

Posted In: RGLS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist